Floatz logo

Esmolol

Dysautonomia

Johns Hopkins UniversitySmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Dysautonomia cohort.

Asset / SponsorPhaseRating
IVABRADINE
Dana-Farber Cancer Institute
Phase 2CCC
Baclofen
University Hospital, Bordeaux
Phase 2CCC
PROPRANOLOL
Johns Hopkins University
Phase 1/2CCC
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Jonathann Kuo, MD
Phase 1CC
Carbon Dioxide
University of Missouri-Columbia
Early Phase 1C
Gilenya
Jochen Vehoff
Phase 4NR

Same molecule, other indications

Esmolol is also rated in:

hemorrhagic strokeDormant
BB
Indicative ·
65 / 100
View asset →
Intraoperative AwarenessDormant
BB
Indicative ·
65 / 100
View asset →
post-operative pain, non-human animalDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →